drugset / Trial / NCT01992341

AMG 386 Drug-Drug Interaction Study With Paclitaxel

NCT01992341

Phase 1 Completed 35 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel

Timeline

Start
2012-07
Primary completion
2013-08
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 80 mg/m2
Subject Trebananib Peptide 15 mg/kg

Indications